- Home
- XERS vs ULCC Comparison
XERS vs ULCC Comparison
Compare XERS & ULCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XERS | ULCC |
|---|---|---|
| Founded | 2005 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Air Freight/Delivery Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | XERS | ULCC |
|---|---|---|
| Price | $7.92 | $5.30 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 10 |
| Target Price | ★ $10.43 | $5.56 |
| AVG Volume (30 Days) | 2.5M | ★ 3.9M |
| Earning Date | 11-06-2025 | 02-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $266,137,000.00 | ★ $3,729,000,000.00 |
| Revenue This Year | $44.37 | $0.13 |
| Revenue Next Year | $27.87 | $14.68 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 42.05 | 1.77 |
| 52 Week Low | $3.14 | $2.89 |
| 52 Week High | $10.08 | $10.26 |
Technical Indicators
Market Signals| Indicator | XERS | ULCC |
|---|---|---|
| Relative Strength Index (RSI) | 59.42 | 61.72 |
| Support Level | $6.88 | $4.71 |
| Resistance Level | $8.42 | $5.57 |
| Average True Range (ATR) | 0.43 | 0.23 |
| MACD | 0.10 | -0.01 |
| Stochastic Oscillator | 70.38 | 98.13 |
Price Performance
Historical ComparisonAbout XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
About ULCC Frontier Group Holdings Inc.
Frontier Group Holdings Inc is an ultra-low-cost carrier whose business is focused on Low Fares Done Right. The company owns a fleet of 120 Airbus single-aisle aircraft, consisting of 13 A320ceos, 82 A320neos, 21 A321ceos and 4 A321neos. The use of these aircraft, their seating configuration, weight-saving tactics, and baggage process have all contributed to the ability to continue to be the fuel-efficient of all the U.S. The Company is managed as a single business unit that provides air transportation for passengers. Majority of revenue is from Domestic flight follow by International.